Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

ABSTRACT:

Background

In Alzheimer's disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing non-demented subjects to putative therapies requires reliable biomarkers for subject selection, stratification, and monitoring of treatment. Neuroimaging allows the detection of early pathological changes, and longitudinal imaging can assess the effect of interventions on markers of molecular pathology and rates of neurodegeneration. This is of particular importance in pre-dementia AD trials, where clinical outcomes have a limited ability to detect treatment effects within the typical time frame of a clinical trial. We review available evidence for the use of neuroimagin

SUBMITTER: Ten Kate M 

PROVIDER: S-EPMC6208183 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature